Dabrafenib Mesylate
Brand name: Tafinlar
Rank #340 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$30.4M
Total Cost
2,377
Total Claims
$30.4M
Total Cost
151
Prescribers
$13K
Cost per Claim
22
Beneficiaries
2,385
30-Day Fills
$202K
Avg Cost/Provider
16
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$30.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $30.4M total
🔎 Data Overview
At $12,802 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $201,529 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $1,383,224 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Dabrafenib Mesylate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Kenneth Ain | Endocrinology | Lexington, KY | 58 | $706K |
| 2 | Mabel Ryder | Endocrinology | Rochester, MN | 46 | $589K |
| 3 | Jiaxin Niu | Hematology-Oncology | Gilbert, AZ | 40 | $572K |
| 4 | Victoria Villaflor | Medical Oncology | Duarte, CA | 40 | $568K |
| 5 | Naifa Busaidy | Endocrinology | Houston, TX | 40 | $448K |
| 6 | Jesse Keller | Internal Medicine | Saint Louis, MO | 27 | $417K |
| 7 | Mario Sznol | Medical Oncology | New Haven, CT | 25 | $379K |
| 8 | Peter Everett | Internal Medicine | Boston, MA | 22 | $344K |
| 9 | Joel Brothers | Medical Oncology | Loma Linda, CA | 24 | $343K |
| 10 | Priyanka Iyer | Endocrinology | Houston, TX | 31 | $343K |
| 11 | Lavanya Tiriveedhi | Hematology-Oncology | Springfield, MO | 26 | $333K |
| 12 | Ted Huang | Hematology-Oncology | Gresham, OR | 24 | $325K |
| 13 | Ammar Sukari | Medical Oncology | Detroit, MI | 29 | $322K |
| 14 | Rajiv Panikkar | Hematology-Oncology | Danville, PA | 22 | $316K |
| 15 | Conor Steuer | Hematology-Oncology | Atlanta, GA | 23 | $314K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 337 | Tafamidis Meglumine (Vyndaqel) | $31.0M | 1,387 |
| 338 | Midodrine Hcl (Midodrine Hcl) | $30.9M | 383,390 |
| 339 | Sarilumab (Kevzara) | $30.5M | 6,822 |
| 340 | Dabrafenib Mesylate (Tafinlar) | $30.4M | 2,377 |
| 341 | Testosterone (Testosterone) | $30.4M | 131,549 |
| 342 | Hydroxyzine Hcl (Hydroxyzine Hcl) | $30.2M | 1,474,936 |
| 343 | Irbesartan (Irbesartan) | $30.1M | 869,928 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology